EUVIMEDEUVIMED entdecken
Crossref

Antibiotic Use and Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma

Shannon S Wu iD, Vasu Divi, John B Sunwoo, Anushka Jetly, Fangdi Sun iD, A Dimitrios Colevas, F Chris Holsinger iD, Jake Lee, Andrey Finegersh iD, Fred Baik iD, Michelle M Chen iD

Head & Neck · 15.07.2026

DOI: 10.1002/hed.70392 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, online erschienen am 15.07.2026. Verfasst von Shannon S Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, California,…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical relevance of antibiotic exposure on immune checkpoint inhibitor (ICI) efficacy in head and neck squamous cell carcinoma (HNSCC) is not well characterized.

Methods

This retrospective study included patients with recurrent/metastatic HNSCC treated between 2015 and 2025. Cox proportional hazards and Kaplan–Meier method modeled overall survival (OS).

Results

Of 316 patients (median age 68 years, 70.9% male), primary tumor site was 40.5% oral cavity, 34.8% oropharynx, 14.9% sinonasal/nasopharynx, 9.8% hypopharynx/larynx. One hundred and forty‐eight (46.8%) patients received antibiotics surrounding ICI. Antibiotics were associated with decreased OS (HR = 1.53, 95% CI 1.15–2.04). On multivariable analysis, while intravenous route of administration and spectrum of antibiotic activity were not risk factors, oral cavity site (HR = 1.72, 95% CI 1.07–2.76), ECOG 2–4 (HR = 2.78, 95% CI 1.70–3.67), PD‐L1 CPS < 1 (HR = 3.16, 95% CI 1.79–5.04), and number of antibiotic classes (HR = 1.37, 95% CI 1.18–1.59) independently predicted decreased OS.

Conclusions

Antibiotic exposure was associated with decreased survival in HNSCC treated with ICI; however, future studies are needed to evaluate potential mechanistic etiologies underlying this association.

Schlagwörter

Stichwörter der Autor:innen

antibioticshead and neck cancerimmune checkpoint inhibitionimmunotherapysquamous cell carcinoma

Autor:innen und Institutionen

  • Division of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, California, USA.
  • Stanford University School of Medicine, Palo Alto, California, USA.
  • Division of Oncology, Department of Medicine, Stanford University, Palo Alto, California, USA.

ORCID-Profile: Shannon S Wu, Fangdi Sun, F Chris Holsinger, Andrey Finegersh, Fred Baik, Michelle M Chen

Zitieren

APA

Wu, S. S., Divi, V., Sunwoo, J. B., Jetly, A., Sun, F., Colevas, A. D., Holsinger, F. C., Lee, J., Finegersh, A., Baik, F., & Chen, M. M. (2026). Antibiotic Use and Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma. Head & Neck. https://doi.org/10.1002/hed.70392

Vancouver

Wu SS, Divi V, Sunwoo JB, Jetly A, Sun F, Colevas AD, et al. Antibiotic Use and Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma. Head & Neck. 2026. doi:10.1002/hed.70392

BibTeX
@article{Wu2026,
  author = {Wu, Shannon S and Divi, Vasu and Sunwoo, John B and Jetly, Anushka and Sun, Fangdi and Colevas, A Dimitrios and Holsinger, F Chris and Lee, Jake and Finegersh, Andrey and Baik, Fred and Chen, Michelle M},
  title = {Antibiotic Use and Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma},
  journal = {Head & Neck},
  year = {2026},
  doi = {10.1002/hed.70392}
}
Kostenlos starten →